Patents by Inventor Allyn T. Londregan

Allyn T. Londregan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED AMIDE COMPOUNDS
    Publication number: 20140315928
    Abstract: The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 23, 2014
    Applicant: Pfizer Inc.
    Inventors: Etzer Darout, Robert Dullea, Julie Jia Li Hawkins, Allyn T. Londregan, Paula M. Loria, Bruce Maguire, Kim F. McClure, Donna N. Petersen, David W. Piotrowski
  • 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES
    Publication number: 20140080756
    Abstract: The present invention provides a compound of Formula (I) a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Pfizer Inc.
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T.M. Orr
  • 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
    Patent number: 8609680
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 17, 2013
    Assignee: Pfizer Inc.
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T. M. Simila
  • 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES
    Publication number: 20110230461
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Application
    Filed: March 16, 2011
    Publication date: September 22, 2011
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T. M. Simila
  • sEH inhibitors and their use
    Patent number: 7994317
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 9, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Yun Ding, Joseph Paul Marino, Jr., Peng Li, Allyn T. Londregan, Barry A. Morgan
  • NOVEL SEH INHIBITORS AND THEIR USE
    Publication number: 20100261743
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2a, R2b, Rya, R6a, A, B, K, L, M, Y, Z, l, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 4, 2008
    Publication date: October 14, 2010
    Inventors: Allyn T. Londregan, Joseph Paul Marino, JR., John Jeffrey McAtee
  • NOVEL sEH INHIBITORS AND THEIR USE
    Publication number: 20100210655
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Inventors: Yun Ding, Allyn T. Londregan, Joseph Paul Marino, JR.
  • Novel sEH Inhibitors and Their Use
    Publication number: 20100069391
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.
    Type: Application
    Filed: November 2, 2007
    Publication date: March 18, 2010
    Inventors: Yun Ding, Joseph Paul Marino, Peng Li, Allyn T. Londregan, Barry A. Morgan